Boehringer Ingelheim's Phase I obesity drug BI 3034701 trial listed as active, not recruiting
A Japan-based Phase I study testing BI 3034701 in healthy volunteers and people with obesity or overweight was registered, with its status now active not recruiting.
Boehringer Ingelheim had one notable trial update this week.
- The Phase I study of BI 3034701, sponsored by Boehringer Ingelheim, is testing multiple rising subcutaneous doses in Japanese participants, split between those with a body mass index of 27.0 kg/m² or more over 16 weeks1 and healthy participants with a BMI of 23.0 to under 27.0 kg/m² over 7 weeks1. The trial's overall status is active not recruiting, with 48 participants actually enrolled1 and a primary endpoint tracking treatment-emergent adverse events assessed as drug-related by the investigator1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.